MBOT

Business Context and Reporting Period

Company: StemCells, Inc. (Note: Request metadata listed "Microbot Medical Inc.", but the filing text identifies the registrant as StemCells, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2002
Business Overview: The company is engaged in the research and development of human therapeutic products, specifically focusing on stem cell technology following a restructuring in 1999. It has not commercialized any products and relies on external financing, grants, and collaborative arrangements to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue for the nine months ended September 30, 2002, was $326,310, a significant decrease from $676,537 in the same period in 2001. The 2001 figure included a one-time $300,000 gain from the assignment of technology rights and a $7.78 million gain from the sale of Modex Therapeutics investments, neither of which occurred in 2002.
• Operating Expenses: Research and development expenses decreased by 9% year-over-year for the nine-month period ($5.52M vs $6.06M), primarily due to the absence of initial facility move costs in 2002, partially offset by increased personnel costs. General and administrative expenses increased by 23% ($3.28M vs $2.66M) because expenses related to Rhode Island facilities, previously booked against a wind-down reserve in 2001, are now recorded as normal operating expenses.
• Liquidity: Cash and cash equivalents decreased from $13.70 million at December 31, 2001, to $6.67 million at September 30, 2002, reflecting a net cash decrease of $7.03 million for the nine-month period.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity Outlook: Management expects current cash resources ($6.67 million) to fund operations into the second quarter of 2003, contingent on the success of a cost reduction program initiated in September 2002. This program includes a 25% reduction in staff and expenses and efforts to reduce operating lease rent.
• Financing Needs: The company has no corporate partnerships for its stem cell technology and must rely on equity/debt offerings, grants, or asset sales to sustain operations beyond mid-2003. An existing $30 million equity line is currently not viable due to trading volume restrictions.
• Nasdaq Compliance Risks: The company is not in compliance with Nasdaq listing requirements. It failed to maintain the $1.00 minimum bid price and has stockholders' equity of approximately $5.0 million, below the required $10.0 million. Failure to regain compliance by January 23, 2003, could result in delisting.
• Lease Obligations: The company faces significant lease obligations for former facilities in Rhode Island (approx. $11.5M operating and $3.7M capital lease commitments). Sublease income is insufficient to cover these costs, and the landlord has asserted a default regarding maintenance defects.
• Unusual Items: The financial statements include "deemed dividends" of $960,000 for the nine months ended September 30, 2002, related to the accretion of 3% Cumulative Convertible Preferred Stock. Additionally, 6% Cumulative Convertible Preferred Stock was automatically converted to common stock in October 2002 (subsequent event).

Investor Verification Checklist

• Cash Runway: Verify the effectiveness of the cost reduction program and the timeline for securing additional financing to bridge the gap beyond Q2 2003.
• Nasdaq Status: Monitor the company's ability to meet the $1.00 minimum bid price and $10 million equity requirement to avoid delisting.
• Rhode Island Liabilities: Assess the risk of default on Rhode Island facility leases and the potential for accelerated debt payments or liquidated damages.
• Revenue Sustainability: Confirm the status of NIH grants and the likelihood of securing new collaborative research agreements to replace one-time revenue sources.
• Preferred Stock Conversions: Review the impact of recent and upcoming preferred stock conversions on common share dilution.